



Clinical Trial Update: 70% Recruitment

Brisbane, Australia, 10th April 2018: Australian biomedical company Factor Therapeutics Ltd announced screening and recruitment activity for the multicentre Phase 2b study of VF001 for venous leg ulcers during the first quarter of 2018 had been one of the strongest to date.

At the end of the first quarter, Factor Therapeutics' VF00102 study achieved 70% of the maximum recruitment target (168 patients), with 116 patients enrolled into the trial.

The first quarter of 2018 saw 26 patients entered the study compared with 28 in the last quarter of 2017.

Factor Therapeutics CEO Dr Ros Wilson said it was important to note that the withdrawal rate also remained lower than expected.

"As we approach the milestone of 'last patient in' (the end of recruitment), we have begun the process of refining the study's final recruitment target," Dr Wilson said.

"To date, more patients have successfully completed the treatment phase than initially estimated. We therefore expect the final recruitment target to be lower than the original 168 patients.

"We are continuing our active management strategy of the trial and a number of initiatives are planned or are under discussion to drive recruitment before the northern summer."

She said a series of local advertising campaigns, started this month (April), would drive recruitment of the final patients in the next quarter.

"We are also continuing to prepare for the Symposium on Advanced Wound Care (SAWC) Spring meeting in Charlotte, North Carolina, where we have two presentations highlighting our technology and the design and execution of the VF00102 study," she said.

"This meeting is also an opportunity to further discussions with potential partners in a face-to-face setting as we work towards raising awareness and interest in both the trial readout and broader portfolio applications of our technology."

-ENDS-

Contact for Further Information:

Dr. Rosalind Wilson
Chief Executive Officer
Factor Therapeutics Limited
r.wilson@factor-therapeutics.com

About Factor Therapeutics

Factor Therapeutics Limited ("Factor") is a biomedical technology company that is developing treatments for acute and chronic wound healing applications. Factor is a clinical stage company with its lead program (VF-001) in Phase II for the treatment of venous leg ulcers (VLUs). The company is also developing solutions for a variety of interventional wound care and serious orphan dermatology conditions. The company's platform technology originates from the Institute of Health and Biomedical Innovation at the Queensland University of Technology (QUT), Australia. Factor's shares are traded on the Australian Securities Exchange (ASX) under the ticker FTT. For more information, please visit <https://factor-therapeutics.com>